Evidence map›Paper›PMID 40425412›Full record

ArticleClinical genitourinary cancer2025

Association Between Rheumatoid Arthritis, Frailty Status, and Mortality in Older Adults with Bladder Cancer.

Maya Swaminathan, Sarah K Holt, John L Gore, Yaw A Nyame, Jonathan Wright, Ami Shah, Jeffrey A Sparks, Una E Makris, Petros Grivas, Maria Suarez-Almazor and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maya SwaminathanDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA.
Sarah K HoltDepartment of Urology, University of Washington, Seattle, WA.
John L GoreDepartment of Urology, University of Washington, Seattle, WA.
Yaw A NyameDepartment of Urology, University of Washington, Seattle, WA.
Jonathan WrightDepartment of Urology, University of Washington, Seattle, WA.
Ami ShahDivision of Rheumatology, Department of Medicine, John Hopkins University School of Medicine, Baltimore, MD.
Jeffrey A SparksDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Una E MakrisUT Southwestern Medical Center, Division of Rheumatic Diseases, Dallas, Texas.
Petros GrivasDepartment of Medicine, Division of Hematology Oncology, Clinical Research Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
Maria Suarez-AlmazorDivision of Rheumatology, University of Texas, Anderson Cancer Center, Houston, TX.
Sarah PsutkaDepartment of Urology, University of Washington, Seattle, WA.
Namrata SinghDivision of Rheumatology, Department of Medicine, University of Washington, Seattle, WA. Electronic address: nasingh@uw.edu.

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
Improving shared decision-making around the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerK23AR079588 · NIAMS · UNIVERSITY OF WASHINGTON · PI Namrata Singh · 2022 to 2026
$821k
Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomesR01AR078484 · NIAMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIORDANO, SHARON HERMES, SUAREZ-ALMAZOR, MARIA E · 2021 to 2023
$675k
Impact of rheumatoid arthritis on survival in older adults with cancerR03AG082857 · NIA · UNIVERSITY OF WASHINGTON · PI SINGH, NAMRATA · 2023 to 2024
$289k
NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INIAMS NIH HHS K23 AR079588NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR078484NIAMS NIH HHS R01 AR080659NIA NIH HHS R03 AG082857
6 · The paper itself

Abstract

backgroundTo evaluate the associations between rheumatoid arthritis (RA) and all-cause (ACM) and cancer-Specific mortality (CSM) in older adults with bladder cancer and examine how frailty may affect these associations.

methodsRetrospective cohort study derived from the Surveillance Epidemiology and End Results (SEER) cancer registry and linked to Medicare claims data (SEER-Medicare). The cohort consisted of patients ≥ 65 years diagnosed with bladder cancer between 2004 and 2017. RA and frailty status were derived using validated administrative algorithms. ACM and CSM as derived from the SEER registry.

resultsFrailty modified the relationship between RA and mortality outcomes (interaction P value for ACM: .002 and for CSM: .007). We observed that RA was associated with a higher risk of CSM (aHR 1.17, 95% CI, 1.01-1.35) and ACM (aHR 1.12, 95% CI, 1.05-1.20) in nonfrail patients. In frail patients with bladder cancer, RA was not independently associated with CSM (aHR 0.81, 95% CI, 0.62-1.06) or ACM (aHR 0.93, 95% CI, 0.83-1.05).

conclusionFrailty is associated with adverse health outcomes. As people are living longer, it is becoming increasingly prevalent among patients with chronic conditions such as RA. We observed that RA is associated with increased risk of ACM and CSM among nonfrail older adults with bladder cancer. The lack of an association between RA and mortality in frail patients with RA suggests that the effect of frailty on mortality may overpower the effect that RA may exert-this information can help prognosticate outcomes in patients with bladder cancer, RA, and frailty.

Indexed as

Arthritis, RheumatoidFrailtyUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMedicareRetrospective StudiesRisk FactorsSEER ProgramUnited StatesEpidemiologyMedicareMultimorbiditySurvivalUrothelial carcinoma

Identifiers

PMID40425412
PMCPMC12270752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.